With its knockout mouse services business under legal attack by competitor Lexicon Genetics Inc., Deltagen Inc. is executing on the other arm of its strategy, development of products based on secreted proteins. Last week, Deltagen obtained exclusive rights to a target selectively expressed by acute myelogenous leukemia stem cells. The company said it will take the target forward internally as its most advanced program and will consider